Liquidia Corporation, trading on NASDAQ under the symbol LQDA, is a biopharmaceutical company focused on developing therapies for rare cardiopulmonary diseases. The company uses its proprietary PRINT Technology to create innovative treatments, particularly for pulmonary hypertension. Liquidia's competitors include other biopharmaceutical firms that specialize in similar therapeutic areas.
On November 3, 2025, Jefferies upgraded Liquidia's stock to a "Buy" rating, with the stock priced at $25.22. This upgrade came alongside an increase in the price target from $43 to $45. The stock has shown a 3.53% increase, or $0.86, reflecting positive market sentiment following the announcement.
Liquidia's Q3 2025 earnings call, held on the same day, featured key executives like CEO Roger Jeffs and CFO Michael Kaseta. The call included participation from major research divisions such as Jefferies LLC and Wells Fargo Securities. This event provided insights into Liquidia's financial performance and strategic plans for future quarters.
The stock's price on the day of the announcement fluctuated between $22.25 and $27.23. Over the past year, LQDA has seen a high of $29.94 and a low of $9.71. The company's market capitalization is approximately $2.17 billion, with a trading volume of 7.25 million shares, indicating strong investor interest.
Liquidia's focus on developing treatments for pulmonary hypertension positions it well in the biopharmaceutical market. The company's strategic direction, as discussed in the earnings call, aims to leverage its proprietary technology to enhance its product offerings and market presence.
